Table 4 Association of treatment outcomes at month 3 with outcomes at month 12.
From: Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV
Response feature | Univariate beta | p | Multivariate beta | p |
|---|---|---|---|---|
Association with gain in BCVA in letters | ||||
Baseline to month 3 mean change in CRT (per 100 nm) | 1.67 (0.45 to 2.90) | 0.02 | 0.51 (0.12 to 2.18) | 0.03 |
Baseline to month 3 mean change in PED volume (per 100 nl) | 0.93 (0.20 to 1.66) | 0.01 | 1.04 (0.07 to 2.01) | 0.03 |
Baseline to month 3 mean change in PED height (per 100um) | 0.01 (− 0.01 to 0.03) | 0.25 | − 0.00 (− 0.03 to 0.02) | 0.78 |
Baseline to month 3 mean change in CV (per 100 nl) | − 0.01 (− 1.28 to 1.25) | 0.98 | 0.22 (− 0.96 to 1.40) | 0.71 |
Association with inactive disease | ||||
Baseline to month 3 mean change in CRT (per 100 nm) | 1.72 (1.16 to 2.80) | 0.01 | 1.32 (1.03 to 2.82) | 0.03 |
Baseline to month 3 mean change in PED volume (per 100 nl) | 1.42 (1.18 to 1.79) | 0.01 | 1.39 (1.11 to 1.82) | 0.01 |
Baseline to month 3 mean change in PED height (per 100um) | 0.91 (0.49 to 1.15) | 0.62 | 1.00 (0.44 to 1.30) | 0.98 |
Baseline to month 3 mean change in CV(per 100 nl) | 1.42 (1.05 to 2.03) | 0.03 | 0.83 (0.44 to 1.48) | 0.56 |
